

[ Thu, May 19th 2022
] - WOPRAI
[ Thu, May 19th 2022
] - WOPRAI
[ Thu, May 19th 2022
] - WOPRAI
[ Thu, May 19th 2022
] - WOPRAI
[ Thu, May 19th 2022
] - WOPRAI
[ Thu, May 19th 2022
] - WOPRAI
[ Thu, May 19th 2022
] - WOPRAI
[ Thu, May 19th 2022
] - WOPRAI
[ Thu, May 19th 2022
] - WOPRAI
[ Thu, May 19th 2022
] - WOPRAI
[ Thu, May 19th 2022
] - WOPRAI
[ Thu, May 19th 2022
] - WOPRAI
[ Thu, May 19th 2022
] - WOPRAI
[ Thu, May 19th 2022
] - WOPRAI
[ Thu, May 19th 2022
] - WOPRAI
[ Thu, May 19th 2022
] - WOPRAI
[ Thu, May 19th 2022
] - WOPRAI
[ Thu, May 19th 2022
] - WOPRAI
[ Thu, May 19th 2022
] - WOPRAI
[ Thu, May 19th 2022
] - WOPRAI
[ Thu, May 19th 2022
] - WOPRAI
[ Thu, May 19th 2022
] - WOPRAI
[ Thu, May 19th 2022
] - WOPRAI
[ Thu, May 19th 2022
] - WOPRAI
[ Thu, May 19th 2022
] - WOPRAI
[ Thu, May 19th 2022
] - WOPRAI
[ Thu, May 19th 2022
] - WOPRAI
[ Thu, May 19th 2022
] - WOPRAI
[ Thu, May 19th 2022
] - WOPRAI
Christopher Raymond Maintained (BPMC) at Hold with Decreased Target to $65 on, May 19th, 2022
Christopher Raymond of Piper Sandler, Maintained "Blueprint Medicines Corporation" (BPMC) at Hold with Decreased Target from $84 to $65 on, May 19th, 2022.
Christopher has made no other calls on BPMC in the last 4 months.
There are 5 other peers that have a rating on BPMC. Out of the 5 peers that are also analyzing BPMC, 3 agree with Christopher's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- David Lebowitz of "Citigroup" Maintained at Hold with Decreased Target to $68 on, Wednesday, April 13th, 2022
- Andrew Berens of "SVB Leerink" Downgraded from Buy to Hold and Decreased Target to $82 on, Thursday, February 17th, 2022
- David Lebovitz of "Morgan Stanley" Maintained at Hold with Decreased Target to $92 on, Tuesday, February 1st, 2022
These are the ratings of the 2 analyists that currently disagree with Christopher
- Bradley Canino of "Stifel" Maintained at Strong Buy with Increased Target to $105 on, Friday, March 4th, 2022
- Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $100 on, Thursday, February 17th, 2022
Contributing Sources